User:Doc James/RfC

Clarification of RfC

Should we state " Simvastatin is relatively low cost." at the end of the 4 paragraph of the simvastatin article.

Based on this 2012 article which states

Simvastatin... is a universally accepted and relatively inexpensive drug.

Elavarasu, S; Suthanthiran, TK; Naveen, D (August 2012). "Statins: A new era in local drug delivery". Journal of pharmacy & bioallied sciences. 4 (Suppl 2): S248-51. doi:10.4103/0975-7406.100225. PMID 23066263. Simvastatin... is a universally accepted and relatively inexpensive drug.{{cite journal}}: CS1 maint: unflagged free DOI (link) And this 2018 review which states

The U.S. patent for simvastatin held by Merck expired on June 23, 2006, which catalyzed a large generic drug launch, with firms from India and Israel ramping up production (18). Costs fell from $1,200 to $40/patient/year, as priced by the Management Sciences for Health International Medical Products Price Guide (19). This reduction helped make statins cost-effective by WHO standards, and in 2007, statins were added to the EML as a therapeutic class. Given its lower cost and off-patent status, we proposed simvastatin as the representative example of the therapeutic class of statins. In 2007, statins were added to the EML with simvastatin as the representative.

Kishore, Sandeep P.; Blank, Evan; Heller, David J.; Patel, Amisha; Peters, Alexander; Price, Matthew; Vidula, Mahesh; Fuster, Valentin; Onuma, Oyere; Huffman, Mark D.; Vedanthan, Rajesh (February 2018). "Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases". Journal of the American College of Cardiology. 71 (5): 564–574. doi:10.1016/j.jacc.2017.11.056.

Support

• Support as proposer. The 2018 review makes it clear why the relatively low cost of this medication is notable. Doc James (talk · contribs · email) 21:31, 30 March 2020 (UTC)

Discussion

Everyone is to put their discussion in their own section.